twoXAR Inc.
Improving health through computation
This article was originally published in Start Up
Executive Summary
TwoXAR Inc. wants to help the biopharma industry make good use of big data. The start-up hopes to change the way drug discovery works, with software that can analyze broad arrays of data – chemical compound libraries, gene expression data, protein interaction networks, protein binding databases, patient records and just about anything else related to drug development – and propose a "short list" of drug candidates with a high probability of making it to the clinic.
You may also be interested in...
AI Drug Developer TwoXAR Raises $10m In Series A
Californian biopharma, TwoXAR, which is using a computational platform to identify drug candidates, de-risks opportunities through preclinical studies, and progresses drug candidates into the clinic, has raised $10m through a series A financing round.
Parkinson’s Disease: Start-Ups Seek Breakthroughs And Money
Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.
Homology Medicines Inc.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.